Skip to main content
CRLCharles River Laboratories InteSell4.0·$326.29

Charles River Laboratories Inte (CRL) Q3 2026 earnings — TrendMatrix coverage

BEAT+4.0% vs estimateEPS $3.09 vs $2.97 estCurrent verdict Sell 4.0/10

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy

Event detail · Q3 2026

Key numbers

Adjusted EPS
$3.09
Estimate
$2.97
Surprise
+4.0%
Revenue (period 2026-09-26)
$982.7M
Score today
4.0/10

Revenue source: xbrl.

Report record · Q3 2026

How the report landed

Charles River Laboratories Inte (CRL) beat the $2.97 estimate with adjusted EPS of $3.09 — a clear 4.0% upside surprise.

Around the report

Coverage in the report window

  • Charles River Q3 2026 Earnings Call Transcript — benzinga, 2026-11-04
  • Charles River Executive Says Overtime Goal Is To Cover Annual Cost Inflation Through Price Increases; Company Not Expect — benzinga, 2026-11-04
  • Charles River Laboratories Announces Third-Quarter 2026 Results — fiscal.ai, 2026-11-04
Current read · as of 2026-11-05

Where TrendMatrix's rating stands now

TrendMatrix currently rates CRL Sell at 4.0/10; no pre/post engine snapshot brackets this report.

4 of the last 4 quarters beat the estimate; this quarter's +4.0% surprise compares with a +5.4% four-quarter average.

What argues against it

  • Concentration risk — Product: DSA segment (59.8%)
  • Target reached (-12.0% upside)
  • Quality below floor (2.9 < 4.0)

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$326.29
Stop
$303.45

The stock trades at 354.7× trailing but 25.6× forward earnings — consensus estimates already build in a substantial earnings recovery.

Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.

Healthcare context

CRL at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Diagnostics & Research
Market cap
$15.58B
P/E (fwd)
25.6
P/E (ttm)
354.7
52-week range
$146.20–$379.63
Off 52-week high
14.1%
RSI (14)
56
Volume vs avg
1.40×
Score today
4.0/10

EPS and the estimate come from Yahoo Finance’s earnings calendar, captured around the report date. That EPS is the adjusted figure analysts forecast, so it can differ from the GAAP diluted EPS in the company’s filing, and consensus estimates vary between data providers. Revenue comes from SEC XBRL company facts where available, yfinance-provisional otherwise. Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home › Stocks › CRL › Earnings › Q3 2026 earnings